MK-677

MK-677 (ibutamoren, MK-0677) is a non-peptide growth hormone secretagogue with a molecular weight of 528.7 Da, developed initially by Merck & Co. and studied extensively in clinical settings for its ability to raise endogenous growth hormone and IGF-1 levels through oral administration. Its development emerged from broader research into ghrelin mimetics during the 1990s, when scientists recognized that stimulating the growth hormone secretagogue receptor could reproduce many of the physiological effects of growth hormone replacement without the need for injections. That distinction — oral bioavailability combined with meaningful hormonal impact — made MK-677 one of the more clinically relevant compounds in its class.

Researchers have studied MK-677 primarily in the context of age-related muscle loss (sarcopenia), diet-induced catabolism, osteoporosis, and growth hormone deficiency in both adults and children. A 1998 study published in the Journal of Clinical Endocrinology & Metabolism examined its ability to reverse diet-induced catabolism in humans, finding that oral MK-677 administration prevented the nitrogen loss associated with caloric restriction. This early finding positioned the compound as a potential intervention for preserving lean mass in catabolic states.

Beyond body composition, researchers investigated MK-677 for its effects on bone metabolism and sleep quality. A 1999 study in the Journal of Bone and Mineral Research reported that the compound increased markers of bone turnover in elderly adults, suggesting possible relevance to osteoporosis management. A 1997 study in Neuroendocrinology found improvements in sleep quality, particularly in REM sleep duration, after prolonged oral treatment — an effect likely linked to the known role of growth hormone secretion in sleep architecture.

Interest in MK-677 has continued into the 2020s, though it remains unapproved and is not legally available as a pharmaceutical in most countries. Its appearance in performance-enhancing supplement stacks has generated several case reports documenting adverse effects, including gynecomastia and potential liver toxicity. These reports have added an important dimension to understanding the compound's real-world risk profile outside controlled research settings.

MK-677 exerts its effects primarily through agonism of the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor expressed in the pituitary gland, hypothalamus, and several peripheral tissues. GHS-R1a is the endogenous receptor for ghrelin, a 28-amino-acid gut-derived peptide that normally signals hunger and stimulates growth hormone release. MK-677 was designed as a synthetic, orally bioavailable mimic of ghrelin, capable of binding GHS-R1a with high affinity without the structural limitations of a peptide molecule.

When MK-677 binds to GHS-R1a in the pituitary, it activates the Gq/11 signaling pathway, leading to phospholipase C activation, increased intracellular inositol triphosphate (IP3) and diacylglycerol (DAG), and a subsequent rise in intracellular calcium. This calcium surge triggers the exocytosis of stored growth hormone from somatotroph cells. The compound also acts at the hypothalamic level, where GHS-R1a activation stimulates the release of growth hormone-releasing hormone (GHRH) and suppresses somatostatin, the hormone responsible for inhibiting growth hormone secretion. These dual actions at the pituitary and hypothalamus produce a synergistic and amplified growth hormone pulse.

The resulting growth hormone elevation stimulates the liver to synthesize insulin-like growth factor 1 (IGF-1), the primary downstream mediator of growth hormone's anabolic and metabolic effects. IGF-1 promotes protein synthesis, inhibits protein degradation, supports bone formation through osteoblast activity, and influences glucose and lipid metabolism. Because MK-677 acts through the endogenous secretagogue pathway rather than introducing exogenous growth hormone, the pulsatile release pattern it produces more closely approximates natural physiological rhythms than continuous growth hormone infusion.

A 2003 study in Growth Hormone and IGF Research analyzed the effect of MK-677 treatment on growth hormone isoform profiles and found that the compound altered the distribution of circulating GH isoforms, consistent with stimulation of endogenous pituitary release rather than recombinant GH administration. This distinction has implications for detection in anti-doping contexts and for understanding how the compound interacts with the somatotropic axis over time. The oral route of administration is a key pharmacological feature, as most peptide-based GH secretagogues require injection due to poor oral bioavailability.

MK-677 has accumulated a meaningful body of clinical trial data across several research areas, spanning body composition, bone metabolism, sleep, and neurodegenerative disease. The breadth of this evidence is unusual for a compound that never reached regulatory approval, and it allows for a more nuanced assessment than is possible for many research peptides.

One of the earliest and most cited human studies, published in the Journal of Clinical Endocrinology & Metabolism in 1998 (PMID 9467534), demonstrated that oral MK-677 reversed diet-induced nitrogen loss in healthy volunteers, effectively countering the muscle-wasting effects of caloric restriction. The study established that oral GH secretagogue therapy could produce clinically meaningful anabolic effects in humans, supporting further investigation in populations prone to catabolism.

Bone metabolism was a central focus of two notable studies. A 1999 investigation published in the Journal of Bone and Mineral Research (PMID 10404019) found that MK-677 increased markers of bone turnover — including osteocalcin and bone-specific alkaline phosphatase — in both healthy and functionally impaired elderly adults, suggesting the compound activated bone remodeling pathways. A 2001 study in the Journal of Clinical Endocrinology & Metabolism (PMID 11238495) examined MK-677 alone and in combination with alendronate in postmenopausal women with osteoporosis, finding that the combination improved bone mineral density markers beyond what alendronate achieved alone, though sample sizes were modest.

Sleep quality was addressed in a 1997 Neuroendocrinology study (PMID 9349662), which reported that prolonged oral MK-677 treatment significantly improved sleep quality in healthy young adults, including increases in REM sleep duration. This finding aligned with known associations between growth hormone pulsatility and slow-wave sleep architecture.

In contrast, a randomized trial published in Neurology in 2008 (PMID 19015485) found that MK-677 produced no clinical benefit in patients with Alzheimer's disease, despite successfully raising IGF-1 levels. The trial highlighted that peripheral hormonal elevation does not necessarily translate into central nervous system benefit, tempering earlier theoretical interest in GH secretagogues for neurodegeneration.

Animal data from a 2018 study in Yonsei Medical Journal (PMID 30450851) examined somatic growth effects in rats, finding that MK-677 increased body weight and IGF-1 levels, supporting the hormonal mechanism observed in human studies. Recent case reports — including a 2024 publication in JCEM Case Reports (PMID 39145153) and a 2025 BMJ Case Reports entry on hepatotoxicity (PMID 40675653) — document adverse effects in individuals using MK-677 as an unsupervised supplement, underscoring the gap between controlled trial conditions and real-world use.

Published clinical trials have used oral MK-677 doses ranging from 10 mg to 25 mg per day in adult human subjects. The 1998 Journal of Clinical Endocrinology & Metabolism study (PMID 9467534) used 25 mg/day in healthy volunteers. The 1999 bone turnover study (PMID 10404019) used 25 mg/day in elderly adults. The 2001 osteoporosis study (PMID 11238495) also used 25 mg/day. The 1997 sleep study (PMID 9349662) used doses in the range of 5 to 25 mg/day. The 2008 Alzheimer's trial (PMID 19015485) used 25 mg/day. These doses were administered under supervised clinical trial conditions. No dose has been approved by a regulatory authority for clinical use.

MK-677 has a documented side effect profile from human clinical trials, which distinguishes it from many research compounds where only animal data exists. That said, the trials were generally short to medium in duration and involved relatively small participant numbers, leaving long-term safety questions unanswered.

The most consistently reported side effects in clinical studies include increased appetite, fluid retention, and transient lower-extremity edema. These effects are mechanistically expected given the compound's ghrelin receptor agonism, which naturally stimulates appetite, and the fluid-retaining properties of elevated IGF-1. A meaningful concern raised in trials involving older adults was an increase in fasting blood glucose and insulin resistance, consistent with the known diabetogenic potential of elevated growth hormone levels. Patients with pre-existing insulin resistance or diabetes are considered a higher-risk population based on these findings.

Joint pain and muscle pain have been reported in some trial participants, again consistent with the known effects of GH elevation. Fatigue and increased somnolence have also appeared in some study records, possibly related to altered sleep architecture or hormonal shifts.

The 2025 BMJ Case Reports publication (PMID 40675653) documented a case of hepatotoxicity attributed to MK-677 use, raising concern about liver safety — particularly in the context of unsupervised supplementation, where purity and dosing cannot be verified. The 2024 JCEM Case Reports paper (PMID 39145153) described reversible gynecomastia and hypogonadism in an individual using a commercial supplement containing MK-677, likely related to the hormonal disruption caused by sustained IGF-1 and growth hormone elevation.

There is no established long-term safety data for MK-677 use beyond the durations studied in published trials. The theoretical risk of promoting growth in insulin-resistant tissues, including any pre-existing neoplastic cells, is a concern raised in the broader GH secretagogue literature, though no MK-677 trial has reported oncological adverse events. Individuals considering MK-677 outside of clinical research settings assume unknown risks that current evidence cannot fully characterize.

MK-677 has been studied in completed clinical trials but has not received FDA approval or equivalent regulatory authorization in major markets. Merck's formal clinical development program did not progress to approval, and the compound exists in a regulatory gray area in many countries. It is not classified as a peptide by drug agencies, which has complicated its scheduling in some jurisdictions.

Active interest in MK-677 continues in the context of age-related muscle loss and frailty, where the oral route of administration remains a practical advantage over injectable GH therapies. No large-scale Phase III trials appear to be currently active based on available published literature. The compound has attracted attention in sports medicine and anti-aging research, though peer-reviewed output in this area remains thin.

Key gaps include: long-term cardiovascular safety data, oncological risk assessment with extended use, and adequately powered trials in sarcopenic populations. Recent case reports documenting hepatotoxicity and endocrine disruption from unsupervised use represent an emerging area of safety literature that warrants formal study.